Amylyx Pharmaceuticals' (AMLX) Relyvrio Receives Approval from FDA
Tweet
Share
E-mail
Get Alerts AMLX Hot Sheet
Join SI Premium – FREE
(Updated - September 29, 2022 4:47 PM EDT)
Amylyx Pharmaceuticals' (NASDAQ: AMLX) Relyvrio received approval from the FDA for treatment of amyotrophic lateral sclerosis in adults.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU approves Arrowhead's plozasiran for rare triglyceride disorder
- Eledon reports Phase 2 kidney transplant drug data at ATC
- Verrica doses first U.S. patient in COVE-3 trial for common warts
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
